Haemonetics (HAE) Projected to Post Earnings on Thursday

Haemonetics (NYSE:HAE) is anticipated to release its Q2 2027 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of $1.29 per share and revenue of $345.15 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2027 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%. The business had revenue of $339.38 million for the quarter, compared to analysts’ expectations of $327.86 million. During the same period in the prior year, the firm earned $1.10 EPS. The business’s quarterly revenue was up 5.5% on a year-over-year basis. On average, analysts expect Haemonetics to post $5.29 EPS for the current fiscal year and $5.73 EPS for the next fiscal year.

Haemonetics Stock Performance

Shares of HAE opened at $120.15 on Tuesday. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.91 and a current ratio of 3.08. The firm has a fifty day moving average of $110.24 and a 200-day moving average of $79.06. The company has a market cap of $5.47 billion, a price-to-earnings ratio of 58.90, a price-to-earnings-growth ratio of 2.37 and a beta of 0.62. Haemonetics has a 1 year low of $49.24 and a 1 year high of $123.77.

Analysts Set New Price Targets

Several brokerages have recently issued reports on HAE. Citigroup boosted their price objective on Haemonetics from $79.00 to $92.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Weiss Ratings raised Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 11th. Barrington Research boosted their price target on Haemonetics from $118.00 to $140.00 and gave the stock an “outperform” rating in a research report on Friday, October 9th. JPMorgan Chase & Co. increased their price target on Haemonetics from $62.00 to $86.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Finally, Wall Street Zen raised Haemonetics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $110.00.

Haemonetics Company Profile

Haemonetics Corporation (NYSE: HAE) is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.

The company’s offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.